G
Guido Kroemer
Researcher at Institut Gustave Roussy
Publications - 1546
Citations - 294816
Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
Beneficial autoimmunity improves cancer prognosis.
TL;DR: In this article, the authors discuss examples of spontaneous as well as therapy-induced auto-immunity that correlate with favorable disease outcomes and make a strong case in favour of this "beneficial auto immunity" being important not only in patients with advanced-stage disease but also in cancer immunosurveillance.
Journal ArticleDOI
Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients
Lenka Kasikova,Michal Hensler,Iva Truxova,Petr Skapa,Jan Laco,Lucie Belicova,Ivan Praznovec,Sarka Vosahlikova,Michael J. Halaska,Tomas Brtnicky,Lukas Rob,Jiri Presl,Jan Kostun,Isabelle Cremer,Isabelle Cremer,Isabelle Cremer,Ales Ryska,Guido Kroemer,Lorenzo Galluzzi,Radek Spisek,Jitka Fucikova +20 more
TL;DR: It is demonstrated that CALR exposure on the surface of primary and metastatic HGSC cells is driven by a chemotherapy-independent ER stress response and culminates with the establishment of a local immune contexture characterized by TH1 polarization and cytotoxic activity that enables superior clinical benefits.
Journal ArticleDOI
Autophagy Mediates Tumor Suppression via Cellular Senescence
TL;DR: Recent data provide molecular insights into the mechanisms whereby oncogene hyperactivation induces autophagy to establish a permanent proliferative arrest commonly known as cellular senescence.
Journal ArticleDOI
Erlotinib antagonizes ABC transporters in acute myeloid leukemia
Elodie Lainey,Marie Sebert,Sylvain Thepot,Marie Scoazec,Cyrielle Bouteloup,Carole Leroy,Stéphane de Botton,Lorenzo Galluzzi,Pierre Fenaux,Guido Kroemer +9 more
TL;DR: It is shown that both erlotinib and gefitinib inhibit transmembrane transporters of the ATP-binding cassette (ABC) family, including P-glycoprotein (P-gp), multidrug resistance-associated proteins (MRPs) and breast cancer resistance protein (BCRP), in acute myeloid leukemia (AML) cells that do not overexpress these pumps.
Journal ArticleDOI
Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia.
Gabrielle Carvalho,C. Fabre,C. Fabre,C. Fabre,Thorsten Braun,Thorsten Braun,Thorsten Braun,J Grosjean,J Grosjean,J Grosjean,Lionel Adès,Fabrice Agou,E Tasdemir,E Tasdemir,E Tasdemir,Simone Boehrer,Simone Boehrer,Simone Boehrer,Alain Israël,Michel Véron,Pierre Fenaux,Guido Kroemer +21 more
TL;DR: The data indicate that malignant cells in high-risk MDS and AML cells critically depend on IKKγ/NEMO to survive, and delineate a novel procedure for their therapeutic removal, through inhibition of IKKα, IKKβ and NEMO oligomerization.